Safety of a meningococcal group B vaccine used in response to two university outbreaks.

Objective: To assess the safety of meningococcal group B (MenB)-4C vaccine.

Participants: Undergraduates, dormitory residents, and persons with high-risk medical conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 12/2013 through 11/2014.

Methods: Adverse events (AEs) were identified by 15 minutes of observation postvaccination, spontaneous reports, surveys, and hospital surveillance.